Recon: FDA approves GSK’s Jemperli for endometrial cancer; Pfizer eyes cost cutting amid falling demand for COVID products
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy